Search Result

Results for "

Polo-like Kinase (PLK)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Polo-like Kinase (PLK) (20) Antibiotic (1) Apoptosis (3) Autophagy (2) CDK (1) DAPK (1) Organoid (1) PI3K (1) Trk Receptor (1)
By Research Areas:	Cancer (17) Cardiovascular Disease (1) Inflammation/Immunology (1)

Inhibitors & Agonists

Antibodies

Targets Recommended: Polo-like Kinase (PLK) NOD-like Receptor (NLR) Toll-like Receptor (TLR) KLF PERK ULK METTL3 ADAMTS IGF-1R LOX-1 Nuclear Hormone Receptor 4A/NR4A FLT3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108597

TC-S 7005 1 Publications Verification	Polo-like Kinase (PLK)	Cardiovascular Disease Inflammation/Immunology
TC-S 7005 is a **Polo-like kinases (Plks) inhibitor with IC₅₀*s of 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk*1, respectively .

HY-18682

Centrinone 15+ Cited Publications LCR-263	Polo-like Kinase (PLK)	Cancer
Centrinone (LCR-263) is a selective and reversible inhibitor of polo-like kinase 4 (PLK4) with a K_i of 0.16 nM.

HY-50877

GSK461364 10+ Cited Publications GSK461364A	Polo-like Kinase (PLK)	Cancer
GSK461364 is a selective, reversible and ATP-competitive **Polo-like kinase 1 (PLK1) inhibitor with a K_i** value of 2.2 nM.

HY-12045

HMN-214 4 Publications Verification IVX-214	Polo-like Kinase (PLK)	Cancer
HMN-214, an orally bioavailable proagent of HMN-176, is an inhibitor of polo-like kinase-1 (plk1), with antitumor activity.

HY-112395

BTO-1

Polo-like Kinase (PLK) Others

BTO-1 is a Polo-like kinase (Plk) inhibitor. BTO-1 is primarily used for phosphorylation and dephosphorylation applications .

BTO-1	Polo-like Kinase (PLK)	Others
BTO-1 is a Polo-like kinase (Plk) inhibitor. BTO-1 is primarily used for phosphorylation and dephosphorylation applications .

HY-13647

HMN-176	Polo-like Kinase (PLK)	Cancer
HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1), without significant effect on tubulin polymerization.

HY-12134

Poloxin 3 Publications Verification	Polo-like Kinase (PLK)	Cancer
Poloxin is a non-ATP competitive **Polo-like Kinase 1 (PLK1) inhibitor that targets the polo-box domain, with an IC₅₀** of appr 4.8 μM.

HY-15159

Cyclapolin 9	Polo-like Kinase (PLK)	Cancer
Cyclapolin 9 is a potent, selective and ATP-competitive **polo-like kinase 1 (PLK1) inhibitor with an IC₅₀** of 500 nM. Cyclapolin 9 is inactive against other kinases .

HY-15155

MLN0905 4 Publications Verification	Polo-like Kinase (PLK)	Cancer
MLN0905 is a potent, orally active **Polo-like kinase 1 (PLK1)** inhibitor. MLN0905 has inhibitory potency against PLK1 with an IC₅₀ value of 2 nM. MLN0905 can be used for the research of cancer .

HY-160624

CD 10899	Polo-like Kinase (PLK)	Cancer
CD 10899 is a hydroxylated metabolite of Volasertib (HY-12137). CD 10899 is pharmacologically active against Polo-like kinase 1 (PLK1) (IC₅₀: 6 nM). Volasertib is an orally active, highly potent and ATP-competitive PLK1 inhibitor. CD 10899 can be used for research of cancer .

HY-10197

Wortmannin Maximum Cited Publications 104 Publications Verification SL-2052; KY-12420	Organoid PI3K Polo-like Kinase (PLK) Autophagy Antibiotic	Cancer
Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC₅₀ of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits **Polo-like kinase 1 (PlK1) and Plk3 with IC₅₀**s of 5.8 and 48 nM, respectively .

HY-12137

Volasertib 15+ Cited Publications BI 6727	Polo-like Kinase (PLK) Apoptosis	Cancer
Volasertib (BI 6727) is an orally active, highly potent and ATP-competitive **Polo-like kinase 1 (PLK1) inhibitor with an IC₅₀** of 0.87 nM. Volasertib inhibits PLK2 and PLK3 with IC₅₀s of 5 and 56 nM, respectively. Volasertib induces mitotic arrest and apoptosis. Volasertib, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models .

HY-12137A

Volasertib trihydrochloride BI 6727 trihydrochloride	Polo-like Kinase (PLK) Apoptosis	Cancer
Volasertib (BI 6727) trihydrochloride is an orally active, highly potent and ATP-competitive **Polo-like kinase 1 (PLK1) inhibitor with an IC₅₀** of 0.87 nM. Volasertib trihydrochloride inhibits PLK2 and PLK3 with IC₅₀s of 5 and 56 nM, respectively. Volasertib trihydrochloride induces mitotic arrest and apoptosis. Volasertib trihydrochloride, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models .

HY-15160

TAK-960 2 Publications Verification	Polo-like Kinase (PLK)	Cancer
TAK-960 is an orally available, selective inhibitor of **polo-like kinase 1 (PLK1), with an IC₅₀** of 0.8 nM. TAK-960 also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-15160B

TAK-960 dihydrochloride 2 Publications Verification	Polo-like Kinase (PLK)	Cancer
TAK-960 dihydrochloride is an orally available, selective inhibitor of **polo-like kinase 1 (PLK1), with an IC₅₀** of 0.8 nM. TAK-960 dihydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 dihydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-15160A

TAK-960 hydrochloride	Polo-like Kinase (PLK)	Cancer
TAK-960 hydrochloride is an orally available, selective inhibitor of **polo-like kinase 1 (PLK1), with an IC₅₀** of 0.8 nM. TAK-960 hydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 hydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-15160C

TAK-960 monohydrochloride	Polo-like Kinase (PLK)	Cancer
TAK-960 monohydrochloride is an orally available, selective inhibitor of **polo-like kinase 1 (PLK1), with an IC₅₀** of 0.8 nM. TAK-960 monohydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 monohydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-124761

Poloppin	Polo-like Kinase (PLK) Autophagy	Cancer
Poloppin is a potent, cell penetrant inhibitor of the mitotic Polo-like kinase (PLK) (IC₅₀=26.9 μM) and prevents the protein-protein interaction via the Polo-box domain (PBD) (K_d= 29.5 μM). Poloppin selectively kills cells expressing mutant KRAS, enhancing death in mitosis. Poloppin is used for the study of KRAS-mutant cancers as single agents, or in combination with c-MET inhibitors .

HY-149912

CZS-241	Polo-like Kinase (PLK) Trk Receptor Apoptosis	Cancer
CZS-241 is an orally active and selective inhibitor of **Polo-like Kinase (PLK) 4 (IC₅₀=2.6 nM). CZS-241 inhibits TRKA with an IC₅₀ value of 2.74 μM. CZS-241 induces apoptosis** and arrests cell cycle at S/G2 phase. CZS-241 shows highly potent antiproliferative activity against leukemia cell lines, and exhibits safety against normal cell lines .

HY-102069

3MB-PP1	Polo-like Kinase (PLK) CDK DAPK	Others
3MB-PP1, a bulky purine analog, is a Polo-like kinase 1 (Plk1) inhibitor. 3MB-PP1 blocks mitotic progression and cell division arise through target Plk1 in in cells expressing analog-sensitive Plk1 alleles. 3MB-PP1 specifically inhibits the activity of analog-sensitive Ssn3 (Cdk8). 3MB-PP1 inhibits Leu93 Mutant Zipper-interacting protein kinase (Leu93-ZIPK; IC₅₀=2 μM). 3MB-PP1 can be used for the research of hypha formation of Candida albicans and cell division .

HY-100789

ON1231320 1 Publications Verification
ON1231320 is a highly specific **polo like kinase 2 (PLK2) inhibitor with an IC₅₀ of 0.31 µM. ON1231320 blocks tumor cell cycle progression in the G2/M phase in mitosis, causing apoptotic** cell death. ON1231320, an arylsulfonyl pyrido-pyrimidinone, has antitumor activity .

PLK1 Antibody PLK1; PLK; Serine/threonine-protein Kinase PLK1; Polo-like Kinase 1; PLK-1; Serine/threonine-protein Kinase 13; STPK13	WB, ICC/IF, IP	Human, Rat
PLK1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 68 kDa, targeting to PLK1. It can be used for WB, ICC/IF, IP assays with tag free, in the background of Human, Rat.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.